Location:Room Stockholm, North Hall (Level 1)
This session will summarise most recent developments in castration sensitive and castration resistant metastatic prostate cancer. In particular, surgical resection of oligometastatic disease, new biomarkers and targets are to be discussed as part of individualised patient care. Furthermore, the upcoming role of immunotherapy in prostate cancer will be presented.
Institutes: University of California Davis, Dept. of Urology, Sacramento, United States of America